Close menu




February 4th, 2020 | 05:50 CET

Aurora Cannabis, EXMceuticals, Tilray - Cannabis development in Portugal

  • Cannabis
Photo credits: pixabay.com

From the street to the clinic. Cannabis had the image of an illegal street drug in most rich countries since the prohibition in the USA in the 1930s. Although cannabis has been used as a medicinal plant for more than 1,000 years, the past decades have been marked by other pharmaceutical products. The market and attitudes towards cannabis are now changing. Doctors, patients, companies and investors see opportunities to profit from this development.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA30207T1049 , CA05156X1087 , US88688T1007

Table of contents:


    Education is the key to success

    Education and research are often the beginning of a success story. In order for development to progress, knowledge and education are an elementary basis for medical change with cannabis. Doctors, patients and companies must work together to test and evaluate the effects of cannabis in medicine.

    With increasing experience and information in databases the acceptance of cannabis in medicine will increase. Thus the use of medical cannabis preparations can be suggested by physicians or simply demanded by patients.

    Improvement of the quality of life

    The use of and experiences with cannabis products are characterized by objective and subjective characteristics. For example, a cannabis product may cause a patient to sleep much better but not to feel any improvement in pain relief. The bottom line, however, is that the quality of life has subjectively increased due to improved sleep.

    Such developments in practice ensure that cannabis products are accepted in medicine. In this context, however, it is important that patients have easy access to medical cannabis products and also that doctors know what they are prescribing for which therapies.

    Opportunities for investors

    Also the companies invest in the development of the cannabis market and here especially experience counts. Aurora Cannabis, EXMceuticals and also Tilray have different approaches and strategies to conquer the market for cannabis products.

    For investors there is the opportunity to participate in the listed companies to be part of it. Even if the share prices of most cannabis companies have been declining in recent months, the trend in use and therapy will continue. It will probably only be a matter of time when this development will be reflected in the stock market prices again.

    Portugal as cannabis centre

    EXMceuticals, a manufacturer of high quality cannabis extracts for use in the pharmaceutical and nutraceutical industry as well as in therapy and cosmetics, announced yesterday that Prf. Dr. Eurico Castro Alves has been appointed to the company's advisory board.

    Commenting on the appointment, Jonathan Summers, CEO of the company, said: "He and EXM share a common goal to establish Portugal as a centre for medical Cannabis healthcare and science. The next step is to have in operation, and licensed, a high-quality ingredients factory that will produce to medical standards and have many industrial applications.”


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Carsten Mainitz on February 4th, 2022 | 12:22 CET

    Novavax, Cardiol, MorphoSys - Here's the second wave of Corona vaccine plays!

    • Cannabis

    The number of new Corona infections reported to the Robert Koch Institute (RKI) within one day has reached an all-time high. 236,120 additional cases were recorded, bringing the number of people in Germany who were confirmed to be infected with Sars-CoV-2 to 10.4 million. However, the number of unreported cases is significantly higher. Vaccine manufacturers from the early days have been able to clear the table in recent months, and now new companies such as Novavax and Valneva are entering the scene. But not all innovative approaches to fighting Corona are on the radar of investors. These are perfect conditions for a second share price wave.

    Read

    Commented by Carsten Mainitz on January 18th, 2022 | 13:07 CET

    Ayurcann, Novavax, Covestro - The stragglers are coming!

    • Cannabis

    Humanity continues to find itself in the clutches of the Corona pandemic, the infection figures are rising, and the demand from politicians for mandatory vaccination is becoming louder and louder. While BioNTech and Pfizer vaccines and Moderna have dominated to date, new vaccine manufacturers are entering the market in the next wave. The situation is similar in the cannabis industry. After a boom about 3 years ago, the market leaders have since lost up to 80% of their value. Legalization and the rise of Cannabis 3.0. will pave the way for new companies.

    Read

    Commented by Stefan Feulner on January 12th, 2022 | 12:54 CET

    Tilray, Ayurcann, Aurora Cannabis - When will the boom 2.0 come?

    • Cannabis

    About five years ago, the boom of cannabis stocks started. Companies like Aurora Cannabis, Canopy Growth and Tilray were able to multiply within a few months. However, the boom was followed by a quick end on the stock market. With corrections of 90% in some cases, the exaggerations were harshly corrected. However, the cannabis market is still in a strong growth phase. The legalization in many countries and the cannabis 3.0 wave promise the companies enormous growth leaps in the next few years. Thus, the steep rise seen at the time could be repeated, at least to some extent.

    Read